Price T Rowe Associates Inc Akero Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $812 Billion
- Q1 2025
A detailed history of Price T Rowe Associates Inc transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 4,817,091 shares of AKRO stock, worth $231 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
4,817,091
Previous 4,321,972
11.46%
Holding current value
$231 Million
Previous $120 Million
62.18%
% of portfolio
0.02%
Previous 0.01%
Shares
18 transactions
Others Institutions Holding AKRO
# of Institutions
281Shares Held
86.5MCall Options Held
1.05MPut Options Held
720K-
Rtw Investments, LP New York, NY7.42MShares$356 Million4.92% of portfolio
-
Janus Henderson Group PLC London, X07.07MShares$340 Million0.16% of portfolio
-
Wellington Management Group LLP Boston, MA5.94MShares$285 Million0.05% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$268 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$251 Million7.15% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.23B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...